Phase 2 trial of CART19 for Orphan Indications Of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

7 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patients with hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT) (Cohort D). Possible procedures include medical record review, apheresis, CART19 infusion, blood draws, physical exams, imaging, and disease assessments through bone marrows and lumbar punctures. If interested in the study or if you have any questions, please contact 267-426-0762.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at oncointake [at] chop.edu or 215-590-5476.

ClinicalTrials.gov Identifier

NCT04276870

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
19-016979
Official Title:
19CT023-Phase 2 Trial of CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T cells (CART19) for Orphan Indications of Pediatric B cell Acute Lymphoblastic Leukemia (B-ALL)
Study Phase:
Phase II
Eligible Age Range:
0 - 29 Years
Gender:
All
Study Categories:
Leader
Amanda DiNofia, MD

Amanda DiNofia, MD